Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 5:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Stress Fracture of Tibia or Fibula
Interventions
Teriparatide, Placebos
Drug
Lead sponsor
University of South Carolina
Other
Eligibility
Not listed
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbia, South Carolina
Terminated No phase listed Observational Accepts healthy volunteers

Brain Circuitry Analysis in Bipolar Disorder

NCT05186077
Conditions
Bipolar Disorder
Interventions
Magnetic Resonance Imaging, Psychiatric testing, Eye-Tracking, Neuropsychology Evaluation
Other
Lead sponsor
Jennifer Sweet
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Not listed No phase listed Observational Accepts healthy volunteers

EXD-959 Orthodontic Brackets and EXD-961 Related Instruments Trial

NCT03606551
Conditions
Malocclusion
Interventions
EXD-959 Bracket System
Device
Lead sponsor
3M
Industry
Eligibility
11 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
5
States / cities
Culver City, California • Wellington, Florida • Northfield, Minnesota + 2 more
Conditions
Tooth Loss
Interventions
Control Collagen Wound Dressing, Test Collagen Matrix
Device
Lead sponsor
McGuire Institute
Industry
Eligibility
18 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Fenton, Michigan
Conditions
Glaucoma
Interventions
Rho-Kinase Inhibitor (AR-12286)
Drug
Lead sponsor
New York Glaucoma Research Institute
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
New York, New York
Conditions
Fluid Retention, Beverage Hydration Index, Hydration Status
Interventions
Test product 1, Test product 2, Placebo
Other
Lead sponsor
Liquid I.V.
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Completed Not applicable Interventional Accepts healthy volunteers

Ibuprofen Inhibits Human Sweet Taste

NCT06291337
Conditions
Treatment of Sweet Taste Receptors Without or With an Oral Rinse of Ibuprofen Solution in Healthy Participants, Treatment of Sweet Taste Receptors Without or With an Oral Rinse of Naproxen Solution in Healthy Participants
Interventions
Inhibition of Sweet Taste by Ibuprofen Oral Rinses, Inhibition of Sweet Taste by Naproxen Oral Rinses
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Brunswick, New Jersey
Conditions
Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Breast Carcinoma, Refractory Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Nodal Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Belinostat, Carfilzomib, Copanlisib Hydrochloride, Daratumumab, Fludeoxyglucose F-18, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Nivolumab, Obinutuzumab, Pembrolizumab, Positron Emission Tomography, Rituximab, Romidepsin, Saline, Trastuzumab
Drug · Biological · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Obesity, Insulin Resistance
Interventions
Fat biopsy during scheduled abdominal surgery, Fat Aspiration, Fish Oil Supplement
Procedure · Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Scottsdale, Arizona
Completed Not applicable Interventional Accepts healthy volunteers

Sexually Dimorphic Effects of GHRH in Adult Growth Hormone Testing

NCT00324064
Conditions
Growth Hormone Deficiency
Interventions
GHRH/arginine stimulation testing
Procedure
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
5 Years to 40 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Kansas City, Missouri
Recruiting Phase 1 Interventional Accepts healthy volunteers

S-Nitrosylation (SNO) Therapy During Autologous Blood Transfusion

NCT03999229
Conditions
Transfusion Related Complication
Interventions
SNO, Normal Saline, Red Blood Cell
Drug
Lead sponsor
James Reynolds
Other
Eligibility
18 Years to 35 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
AML (Acute Myeloid Leukemia), Multiple Myeloma Refractory
Interventions
Soursop tea
Biological
Lead sponsor
Roger Strair
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Camden, New Jersey
Active, not recruiting No phase listed Observational

Non-contrast DWI for Supplemental Screening

NCT03607552
Conditions
Breast Cancer
Interventions
Non-contrast DWI, Non-contrast MRI
Device
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
269 participants
Timeline
2018 – 2029
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Completed Not applicable Interventional Accepts healthy volunteers Results available

Restoration of Spectral Resolution With Hearing-aid Amplification

NCT03850678
Conditions
Hearing Loss
Interventions
Hearing Aid
Device
Lead sponsor
University of Nebraska Lincoln
Other
Eligibility
40 Years to 75 Years
Enrollment
209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Matching Placebo, Nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
11
States / cities
Danbury, Connecticut • Sarasota, Florida • Skokie, Illinois + 8 more
Conditions
Irregular; Contour of Cornea
Interventions
contact lens insertion solution
Device
Lead sponsor
Jennifer Fogt
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Heat Therapy, Functional Capacity, and Vascular Health in Older Adults

NCT05706181
Conditions
Aging Well, Walking, Difficulty, Hyperemia
Interventions
Home-based leg heat therapy, Home-based sham therapy
Other
Lead sponsor
University of North Texas Health Science Center
Other
Eligibility
55 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Fort Worth, Texas
Conditions
Cystic Fibrosis
Interventions
Candy Glucose Tolerance Test
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
10 Years to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Rochester, Minnesota
Recruiting Not applicable Interventional Accepts healthy volunteers

Developing Fast Pediatric Imaging

NCT03761121
Conditions
Pediatric Low-grade Gliomas
Interventions
Wave-CAIPI
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
0 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
Interventions
Placebo, Diazoxide Oral Suspension, 2 mg per kg per dose, Deuterated water (2H2O/D2O), 70%, Insulin Suppression Test (IST)
Drug · Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Conditions
Mental Health, Conflict
Interventions
Parent-child intervention, Self-study Intervention
Behavioral
Lead sponsor
University of Notre Dame
Other
Eligibility
4 Years and older
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
3
States / cities
Fort Wayne, Indiana • Indianapolis, Indiana • Notre Dame, Indiana
Conditions
Dementia, Parkinsonism, Mild Cognitive Impairment, REM Sleep Behavior Disorder
Interventions
I-123 Ioflupane solution injection prior to SPECT scan (DaTscan), Single photon emission computed tomography (SPECT) scan
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 90 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Sunburn
Interventions
6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation, 6% Bemotrizinol (BEMT) dispersion in petrolatum, Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT, Petrolatum vehicle, 0.9% Saline, Sodium Lauryl Sulfate 0.1% (SLS), Undosed patch
Drug · Other
Lead sponsor
dsm-firmenich Switzerland AG
Industry
Eligibility
18 Years to 75 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Piscataway, New Jersey
Conditions
Obesity
Interventions
Exendin 9-39 and Sitagliptin, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
New York, New York